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Recent progress in genome-wide technologies and the analysis of small cell numbers has allowed researchers to capture transcriptional and epigenetic snapshots of rare cell populations undergoing cell fate transitions in different biological contexts. These analyses have yielded important insights into the type and sequence of molecular changes inherent to transcription-factor-induced pluripotency, germ-cell reprogramming and cellular transformation. A common theme emerging from these studies is that nascent iPSCs, developing germ cells and premalignant cells use different as well as overlapping mechanisms to alter cell identity. The aim of this Review is to define those transcriptional, chromatin and epigenetic changes that endow specialized cells with pluripotency as well as the molecular barriers that resist cell fate change.
Mechanisms of induced pluripotency
Acquisition of induced pluripotency is a slow (around 2 weeks) and inefficient (0.1-3%) process 1, 3 , indicating that transcription factors need to overcome a series of epigenetic barriers that have been gradually imposed on the genome during differentiation to stabilize cell identity and to prevent aberrant cell fate changes. Earlier work has shown that cell populations expressing OKSM pass through a sequence of distinct molecular and cellular events (Fig. 1) . Fibroblasts initially downregulate markers associated with the somatic state and subsequently activate genes associated with pluripotency, suggesting an ordered process 4, 5 . As soon as nascent iPSCs activate endogenous core pluripotency genes including Oct4, Sox2 and Nanog, they acquire a self-sustaining pluripotent state and no longer require exogenous factor expression. The latter events also coincide with the activation of the silenced X chromosome in female somatic cells, the upregulation of telomerase and the acquisition of immortality, which are hallmarks of cultured pluripotent cells 5, 6 . In the following sections, we will review our current knowledge of the way in which overexpressed transcription factors engage with chromatin, collaborate with epigenetic regulators and integrate extracellular signals to reprogram cellular identity (Fig. 2) .
Transcription factors drive cell fate change
The most commonly used combination of reprogramming transcription factors comprises OKSM, and we will therefore primarily focus on this set of factors 3 . Earlier results have suggested that c-Myc and OKS play distinct parts during the acquisition and maintenance of pluripotency 7 . Briefly, OKS is the minimal set of factors required for iPSC generation from many cell types under classic reprogramming conditions (in the presence of serum and the cytokine leukaemia inhibitory factor, LIF). OKS cooperatively suppress lineage-specific genes and activate embryonic stem (ES)-cell-related genes, resulting in the establishment of a self-sustaining pluripotency network 7 . By contrast, ectopic c-Myc expression significantly enhances and accelerates reprogramming but is dispensable for iPSC formation 8, 9 . c-Myc expression functions early during reprogramming, presumably by stimulating cell proliferation and inducing a metabolic switch from an oxidative to a glycolytic state that is typical of pluripotent cells 10, 11 . More recent evidence suggests that c-Myc may also contribute to reprogramming by inducing pause release and promoter reloading of RNA polymerase, leading to transcriptional amplification of target genes 12, 13 . It is worth noting that each of the original four reprogramming factors has been functionally replaced by either related transcription factors, upstream epigenetic modifiers, microRNAs (miRNAs) or small compounds 1 . Moreover, iPSCs have been derived with molecules that do not contain any of the original transcription factors 14, 15 , indicating a remarkable flexibility and redundancy among reprogramming factors (Fig. 2) . For example, a recent report demonstrated that the core pluripotency factors Oct4 and Sox2 can be substituted for by early lineage specifiers such as Gata3 and Geminin 16 . These molecules have been associated with mesendodermal and ectodermal differentiation, respectively; they also mutually repress the other respective lineage program, suggesting that the suppression of these major differentiation pathways is sufficient to trigger iPSC induction. This idea is consistent with the observation that many classic pluripotency factors, including Oct4, Sox2 and Nanog, participate in early lineage decisions and hence may also be considered to be lineage specifiers 17 . A prediction that follows from these results is that transcription factors that stabilize a defined somatic state should be inhibitory to OKSM-mediated reprogramming. Indeed, depletion of the B-cell-specifying transcription factor Pax5 or ectopic expression of its antagonist C/EBP-α allows the reprogramming of terminally differentiated B cells 18 . Conversely, forced expression of differentiation-associated transcription factors, in combination with OKSM, significantly impairs iPSC formation by sustaining a somatic gene expression program and preventing activation of pluripotency genes 19 .
Together, these findings demonstrate that reprogramming transcription factors have to achieve two key tasks, namely the extinction of the somatic program and the induction of a stable pluripotent state typical of ES cells.
Different types of chromatin targets
Developmental progression from pluripotent stem cells through progenitors to terminally differentiated cells is accompanied by a gradual deposition of repressive histone marks, followed by chromatin compaction [20] [21] [22] . A key question is therefore how reprogramming transcription factors dismantle somatic chromatin and establish an epigenetic state that is compatible with pluripotency. Recent studies assessing OKSM occupancy and histone marks early during the reprogramming of mouse and human fibroblasts into iPSCs have provided the first clues for answering this question 10, 23, 24 . Combining these observations, one may categorize OKSM targets into three classes of loci based on chromatin accessibility, the requirement for additional remodelling and the kinetics of transcriptional activation (Fig. 3a) . Genes with an 'open' chromatin state in somatic cells comprise the first group of targets, characterized by increased DNaseI hypersensitivity, active di-and trimethylation of histone H3 lysine 4 (H3K4me2 and H3K4me3) and the ability to bind OKSM immediately. Downregulated somatic genes and genes linked to a mesenchymal-to-epithelial transition (MET), which specifies early stages of reprogramming 25 , fall into this group 24 . A second class of early bound OKSM targets includes distal regulatory elements, which seem to require additional chromatin remodelling for transcriptional activation 24 . A subgroup of these elements carries the H3K4me1 mark and exhibits nucleosome depletion as well as DNase I hypersensitivity, which are chromatin features characteristic of 'permissive enhancers' . Permissive enhancers typically bind transcription factors before their associated promoter regions and prior to transcriptional activation 26 . The MyoD locus exemplifies this group of enhancers; ectopically expressed Oct4 initially binds to the MyoD enhancer, triggering crosstalk with its promoter and subsequent acquisition of a poised chromatin state 26 . Another subset of distal regulatory elements comprises DNase-I-resistant loci that are unable to bind c-Myc alone 24 .
Early pluripotency genes such as Sall4 belong to this group. Interestingly, occupancy of these targets by OKS facilitates binding of c-Myc. This observation thus identifies OKS as 'pioneer factors' , defining the ability of transcription factors to bind closed somatic chromatin and allow chromatin remodelling as well as recruitment of other transcription factors and cofactors 24 . Broad heterochromatic regions enriched for the repressive H3K9me3 mark constitute a third set of OKSM targets. Genes within this category comprise core pluripotency genes, such as Nanog and Sox2 (ref. 24) . These regions are refractory to immediate OKSM binding and seem to require the most extensive chromatin remodelling for transcriptional activation. Of interest, refractory domains are reminiscent of broad chromatin regions enriched for the H3K9me2 mark, termed large organized chromatin K9-modification (LOCK) 27 . LOCKs are generally underrepresented in pluripotent cells and associated with repression of lineage-specific genes in differentiated cells 27 . Bivalent genes constitute a separate group of chromatin targets that are marked by both active H3K4 methylation and repressive H3K27 methylation in iPSCs or ES cells 28 . Genes within this category are transcriptionally silent in ES cells and iPSCs but poised for rapid activation on lineage commitment. Although the actual number and relevance of bivalent promoters remain controversial 29 , induced pluripotency gradually restores these domains to an ES-cell-like pattern 10, 23 . The transcription factor Utf1 has recently been implicated in the regulation of bivalency by a dual mechanism that involves deposition of the repressive H3K27me3 mark and degradation of residual transcripts 30 . Notably, Utf1 expression can substitute for some of the original reprogramming factors, providing indirect evidence that the establishment of bivalent promoters may be an important step during the acquisition of pluripotency 14 . Together, these results illustrate how the initial chromatin state of pluripotency-related and somatic genes determines if and when they become occupied and transcriptionally regulated by OKSM in the course of reprogramming. They further suggest that certain histone marks (for example, H3K9 methylation) act as potent barriers that resist acquisition of pluripotency. We will therefore next focus on the enzymes that deposit or remove these marks and their impact on cellular reprogramming.
Role of histone-modifying enzymes
Histone marks and chromatin structure are regulated by histonemodifying enzymes, or 'writers' , such as histone methyltransferases (HMTs) and histone acetyltransferases (HATs), and 'erasers' such as histone demethylases (HDMs) and histone deacetylases (HDACs) (Fig. 2) . These enzymes function as co-activators or co-repressors of OKSM at different stages of reprogramming and can profoundly influence iPSC derivation. For example, recruitment of polycomb repressive complex 2 (PRC2), which deposits the repressive H3K27me3 mark, and inhibition of Dot1L (which establishes the active H3K79me2 and H3K79me3 marks) have been associated with the downregulation of somatic genes early in reprogramming 31, 32 . Accordingly, loss of PRC2 abrogates whereas loss of Dot1L enhances iPSC formation. Activation of the H3K36 HDMs Jhdm1a and Jhdm1b 33 increase transcription factor accessibility and result in more efficient iPSC generation from somatic cells 24, 36, 37 . Altogether, these results demonstrate that histone code writers and erasers are essential components of iPSC formation by either maintaining the somatic state or assisting in the transcription-factor-induced establishment of pluripotency.
Reprogramming transcription factors have been reported to directly interact with histone-modifying enzymes, providing a mechanistic explanation for how they may alter chromatin and cell state during induced pluripotency. Examples include the H3K27 HDM Utx 14 and the H3K4me3 'effector' Wdr5 (ref. 38 ) that bind to Oct4 protein and co-occupy many genomic targets in ES cells, thus keeping them in a transcriptionally active state. Depletion of either molecule blunts iPSC formation owing to a failure to activate pluripotency genes 14, 38 . Oct4 may have a very specific role in recruiting epigenetic regulators to target genes compared with Sox2, Klf4 and c-Myc, because it cannot be replaced by related family members during induced pluripotency 8 . In agreement, deletion of a linker domain on Oct4, which is absent on other POU domain family members and associates with chromatin remodellers implicated in reprogramming, abrogates iPSC formation 39 . Intriguingly, some reprogramming-associated cofactors function in a chromatin-independent manner. For example, the H3K27 HDM Jmjd3 blocks reprogramming not only by activating the Ink4a/Arf locus but also by targeting the methyl-lysine effector protein Phf20 for ubiquitination; Phf20 is required to activate Oct4 transcription in collaboration with Wdr5 (ref. 34) . Overall, these and other 7 examples document the physical association of reprogramming transcription factors with a variety of histone modifiers and exemplify the diverse mechanisms by which they assist in reinstating pluripotency in somatic cells.
DNA methylation safeguards cell identity
DNA methylation is considered to be the most stable epigenetic modification, which confers permanent gene silencing during development and in the adult. Changes in histone modifications typically precede the removal or deposition of DNA methylation marks during differentiation 20 . Similarly, DNA methylation changes almost exclusively occur at the end of the reprogramming process and after chromatin changes have taken place 10 , indicating a hierarchy of events that recapitulates normal development (Fig. 1) . DNA methylation is established by the de novo methyltransferases Dnmt3a and Dnmt3b and preserved by the maintenance methyltransferase Dnmt1 (ref. 40) . Although DNMT3a knockdown promotes iPSC formation in human cells 31 , deletion of the mouse enzymes Dnmt3a and Dnmt3b has no consequence for cellular reprogramming 41 . This surprising finding suggests that the silencing of lineage-specific genes is mainly achieved through alternative mechanisms such as deposition of repressive H3K27 methylation, which is consistent with the essential role of PRC2 in iPSC formation 32 . In contrast to the dispensability of de novo methylation for iPSC formation, DNA demethylation of pluripotency genes seems to be crucial for faithful reprogramming. Demethylation can occur by either active or passive mechanisms (see Review by Kohli and Zhang 40 ), both of which have been implicated in iPSC generation. Downregulation of Dnmt1 in reprogramming intermediates facilitates their transition towards authentic iPSCs, consistent with the supportive role of passive, replication-dependent demethylation in iPSC formation 42 . Enzymes associated with active DNA demethylation have a more direct link with iPSC formation (Fig. 1 ). TET proteins catalyse the hydroxylation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), which serves as a substrate for TDG-mediated base excision repair into unmodified cytosine 40 . Shortly after overexpression of OKSM, Tet2 induces hydroxymethylation of key pluripotency genes such as Nanog and Esrrb, priming them for subsequent demethylation and transcriptional activation (Figs 1 and 3b) 43 . Interestingly, proteomic and genomic analyses revealed that Tet1 and Tet2 directly interact with Nanog and co-occupy many pluripotency targets in ES cells, implicating Nanog in the targeting of Tets 44 . In agreement, simultaneous overexpression of Tet1 or Tet2 together with Nanog significantly enhances, whereas depletion of Nanog or Tet2 abrogates, iPSC formation [43] [44] [45] . Moreover, Tet1 overexpression can compensate for exogenous Oct4 expression during cellular reprogramming, providing genetic evidence that Tet1 contributes to the activation of somatically silenced pluripotency genes 46 . A role for activation-induced deaminase (Aid) in DNA demethylation during transcription-factor-induced reprogramming has also been reported, although the underlying mechanisms are incompletely understood 40 . Inefficient DNA demethylation or remethylation has further been suggested to be the main reason for the 'epigenetic memory' observed in many iPSC lines. This term describes cell-type-of-origin-dependent transcriptional and epigenetic patterns that can influence the differentiation potential of iPSCs 1 . Of note, genomic regions that fail to undergo DNA demethylation towards an ES-cell-like state in human iPSCs were shown to be decorated by broad H3K9me3 domains in somatic cells 47 , and some of these areas overlap with the above mentioned 'refractory domains' that are inaccessible to OKSM early in reprogramming 24 . These findings therefore suggest that promiscuous OKSM binding or lack of OKSM binding to targets could explain some of the observed differences between ES cells and iPSCs. It will be interesting to assess whether manipulation of H3K9 HDMs or HMTs is sufficient to erase epigenetic memory in iPSCs.
Three-dimensional chromatin architecture in reprogramming Accumulating evidence suggests that local and three-dimensional (3D) chromatin architecture provide additional levels of gene regulation in pluripotent stem cells (see Review by de Laat and Duboule 48 ). However, their roles in cellular reprogramming are incompletely understood. Local chromatin architecture defines the position and density of nucleosomes as well as the presence of histone variants (Figs 2 and 3c) 49 . Histone variants usually modify the ability of nucleosomes to undergo remodelling and to accommodate active or repressive histone modifications. The histone variant macroH2A has previously been associated with resistance to efficient chromatin remodelling 49 . In agreement, the presence of macroH2A potently inhibits transcription-factor-induced reprogramming of somatic cells to pluripotency by maintaining pluripotency loci in a repressed state [50] [51] [52] . Local chromatin architecture is regulated by diverse remodelling complexes, which also affect iPSC formation (Fig. 2) . Components of the SWI-SNF complex, such as Brg1, Baf155 and Brm, are directly recruited by Oct4 to targets in order to relax chromatin structure and facilitate binding of other transcription factors 53 . This finding thus corroborates that Oct4 has a role as a pioneer factor by influencing local chromatin structure at silenced targets. Similarly, the CHD remodelling factor Chd1 has been proposed to actively open chromatin during factor-induced reprogramming, and knockdown of its gene impairs iPSC formation 54 . By contrast, members of the repressive NURD complex including Hdac1 and Mdb3, which are crucial for heterochromatin compaction, inhibit reprogramming and their gene knockdown strongly increases the efficiency of iPSC generation 55, 56 . Interestingly, Mbd3 associates with loci enriched for Tet1 and 5hmC in ES cells and its expression is essential for global levels of 5hmC 57 . The latter observation may explain the discrepancy between the observed early deposition of 5hmC at pluripotency loci 43 but its delayed conversion into unmodified C during iPSC generation 10 ; Mbd3 may be recruited to these hydroxymethylated pluripotency promoters and block immediate demethylation until unidentified co-activators relieve Mbd3-mediated gene repression.
In addition to local chromatin structure, 3D chromatin architecture has been implicated in pluripotency, differentiation and reprogramming (Fig. 3d ) 48 . Differentiation of ES cells is accompanied by repositioning of pluripotency genes from the nuclear centre to the nuclear periphery 58 and a disruption of promoter-enhancer looping at key pluripotency loci such as Oct4 (refs 59, 60) and Nanog 54, 55 . This raises the question of whether and how 3D chromatin structure is restored in iPSCs. A recent study identified complex pluripotency specific long-range interactions of the Nanog locus, which become rearranged during differentiation and are largely restored during reprogramming 61 . The establishment and maintenance of this network is dependent on mediator and cohesin complexes, which are known to orchestrate long-range chromatin interactions 60 . Interestingly, subunits of these complexes were found to directly interact with reprogramming factors 61, 62 and their knockdown inhibited iPSC formation 61 . Extending these findings, long-range chromatin interactions around the Oct4 promoter were recently implicated in the reprogramming of murine and human cells 62, 63 . Importantly, these interactions took place specifically in those rare cells that were poised to form iPSCs, and they preceded transcriptional activation, suggesting a causal effect for 3D chromatin structure on transcription. These results -together with previous studies documenting a role for Oct4 and Klf1 (highly similar to Klf4) in mediating long-range chromatin interactions 64, 65 -support the idea that reprogramming factors do not merely activate or silence genes but also function as chromatin organizers, which rearrange chromatin architecture from a somatic to a pluripotent state. Furthermore, this interpretation is consistent with the recent discovery of 'superenhancers' , which are broad distal regulatory elements characterized by cooperative and excessive binding of mediator components and cell-type-specific transcription factors, such as Esrrb and Klf4, in ES cells 66 . Given the documented role of super-enhancers in controlling the expression of master regulatory genes in different cell types, it is likely that the resetting of somatic-specific to pluripotency-specific super-enhancers constitutes another roadblock for iPSC formation. The dynamics of this switch during induced pluripotency and the potential role of super-enhancers in 3D chromatin architecture certainly warrants further investigation.
Cell signalling and chromatin
External cues are crucial to direct cells expressing OKSM towards a stable pluripotent state and to prevent acquisition of alternative cell fates 7 . Extracellular signals can either support or inhibit iPSC formation (Fig. 2) . For example, dual chemical inhibition of the Gsk3b, and Erk1 and Erk2 pathways (known as the 2i condition) enhances the transition of partially reprogrammed cells into iPSCs 67 . Similarly, activation of the Jak-Stat3 pathway by the cytokine LIF is limiting for iPSC formation 68 . By contrast, the TGF-β pathway negatively affects iPSC generation and suppression of the pathway by chemical inhibitors significantly increases the acquisition of pluripotency 69, 70 . Recent data offer new mechanistic insights into how external signals communicate with chromatin structure in pluripotency and reprogramming. For instance, the downstream effector of LIF signalling, Stat3, requires the chromatin remodeller subunit Brg1 to keep targets accessible and prevent their repression by the PRC2 complex 71 . Moreover, culture of ES cells in 2i endows cells with a so-called naive or ground state that is characterized by altered H3K27me3 distribution and a decreased number of bivalent promoters as well as global DNA hypomethylation 72, 73 . Mechanistically, growth of ES cells in 2i induces activation of the transcription factor Prdm14, which directly represses Dnmt3a and Dnmt3b and inhibits differentiation-inducing Fgfr signalling 72 . It is important to mention here that signalling molecules can also have opposite effects on different stages of reprogramming. Bone morphogenetic proteins promote an early MET in an miRNA-dependent manner 25 , whereas they block the late conversion of partially been shown to strongly enhance the efficiency and kinetics of reprogramming 75 and to increase the quality of mouse iPSCs by preventing aberrant hypermethylation 76 . Ascorbic acid presumably functions both as an antioxidant and as a cofactor for specific epigenetic modifiers such as the H3K36 HDMs Jmjd1a and Jmjd1b 33 . Furthermore, ascorbic acid has been suggested to be a cofactor for H3K9 HDMs and Tet enzymes, according to recent studies that reported a global decrease of the repressive H3K9me2 and H3K9me3 marks 36 and genome-wide DNA hypomethylation 77 , respectively, in nascent iPSCs exposed to this compound. Together, these observations provide compelling new evidence for the tight communication between reprogramming-associated signalling molecules and transcription factors in order to rewire epigenetic regulatory circuits.
Sequence of molecular events
An unresolved question is whether the rare cells that give rise to iPSCs undergo a defined sequence of transcriptional and epigenetic events that are essential for successful reprogramming. Different approaches have been used to resolve this issue. A number of reports used surface marker combinations to prospectively identify those rare cell populations that are destined to form iPSCs 10, [78] [79] [80] . One of these studies identified two major waves of gene expression changes that coincided with the early extinction of somatic genes and with the late activation of core pluripotency genes, respectively 10 . The lack of major transcriptional changes during the intermediate phase suggested that cells undergo gradual epigenetic alterations to prime the genome for transcriptional activation of pluripotency genes. In agreement with this is the observation that histone marks associated with pluripotency enhancers are established at early and intermediate stages of reprogramming, whereas DNA methylation changes occur late, coinciding with transcriptional activation of associated genes 10 . Integrating observations from other studies, this intermediate period is also characterized by the establishment of pluripotency-specific long-range chromatin interactions 61, 62 and Tet-mediated conversion of 5mC into 5hmC at pluripotency promoters 43 , further supporting the interpretation that cells undergo a series of chromatin changes in preparation for stable pluripotency.
An independent study analysed transcriptional changes of 48 genes in single cells undergoing reprogramming 15 and concluded that the initial response to reprogramming factor expression is quite heterogeneous and consistent with a stochastic process. However, later events, leading to the activation of pluripotency genes, occur in a hierarchical manner. This analysis led to the inference that activation of the endogenous Sox2 locus is a crucial upstream event in cells that undergo successful reprogramming. A parallel study examined clonal populations of cells expressing OKSM and defined 'maturation' and 'stabilization' phases of reprogramming that were distinguished by differential expression of pluripotency genes 81 . Unexpectedly, the authors discovered that the transition to the stabilization phase is dependent on a different set of factors (for example, GDNF signalling and meiosis genes) from those that control maintenance of pluripotency.
Several groups have reported transient upregulation of developmental regulators, such as epidermal, extra-embryonic and epiblast-associated genes, at intermediate stages of reprogramming 10, 16, 42, 74, 78 (Fig. 1) . Although the molecular mechanisms underlying this observation remain elusive, it is tempting to speculate that reprogramming intermediates transiently pass through a state with increased developmental plasticity that could represent stages of normal development 7 . Alternatively, these genes might be activated as a consequence of aberrant transcription-factor binding 11 or unspecific effects incurred by small compounds 82 . Regardless, recent studies showed that depletion of some of these transiently expressed genes impairs reprogramming into iPSCs, suggesting functional relevance 79, 82 .
In conclusion, although the overall gene expression trends are similar among different studies, variability related to the exact sequence of molecular events and the relative contribution of stochastic and deterministic events remain to be resolved. Another fundamental question that needs to be addressed is whether cells expressing alternative reprogramming factors pass through the same sequence of events described here, and encounter the same barriers as cells expressing OKSM. This question is particularly relevant with respect to reprogramming approaches that involve small compounds 82 or transcription factors that have not been directly associated with the core pluripotency network 16 .
Lessons from other reprogramming systems
In this section, we will compare induced pluripotency with other processes involving epigenetic reprogramming such as SCNT, cell fusion and germ-line specification with the goal of identifying mechanistic similarities and differences (Table 1) .
Somatic cell nuclear transfer
Remarkably, the somatic gene expression program is downregulated within 22 hours of SCNT in mice (D. Egli, personal communication) 83 . This observation is reminiscent of iPSC formation and suggests that extinction of somatically expressed genes is rapid and efficient in both approaches. Somatic Oct4 activation after SCNT occurs with similar kinetics (24-36 hours) 83 and has been suggested to require Tet3 (ref. 84) , whereas it takes a minimum of 8 days to detect Oct4 expression during induced pluripotency 83 and this process seems to involve Tet2 (ref. 43 ). This marked difference in pluripotency gene activation poses the key question of whether SCNT and induced pluripotency depend on the same transcription factors for reprogramming; both Oct4 and Sox2 are in fact detectable in oocytes. Schöler and colleagues recently addressed this question by genetically depleting maternal Oct4 from mouse oocytes before SCNT 85 . Surprisingly, loss of Oct4 did not abrogate the oocyte's ability to reprogram somatic nuclei, indicating compensation by other factors. The identification of the oocyte-enriched Glis1 protein 86 , capable of enhancing iPSC formation in the context of OKS expression, supports this hypothesis.
A key molecular event that distinguishes induced pluripotency from SCNT is the rapid histone exchange between somatic nucleus and oocyte, as demonstrated in Xenopus SCNT experiments. Specifically, the somatic linker histone H1 is replaced within hours of SCNT for the oocyte-specific counterpart B4, and this process is essential for pluripotency gene activation in reconstructed oocytes 87 . This particular exchange of histone types might contribute to reprogramming by depleting somatic chromatin from epigenetic repressors known to interact with histone H1, such as Dnmt1 and Dnmt3b, and H3K9 methyltransferases 88, 89 . Concomitant with the replacement of 'repressive' histone variants, incorporation of 'active' histone variants including H3.3 and H2A.X into the somatic chromatin facilitates efficient chromatin remodelling of embryonic genes 90, 91 . Despite these effective mechanisms, some epigenetic marks including those of the silenced X chromosome (Xi) in female somatic nuclei seem to be more recalcitrant to remodelling by the oocyte compared with pluripotency genes, indicating differential susceptibility of some genomic loci to the oocyte's reprogramming machinery 92 . The relative resistance of X reactivation to efficient remodelling during Xenopus SCNT has been functionally linked to the repressive histone variant macroH2A, because its knockdown resulted in a more efficient reactivation of the Xi 92 . Thus, the eviction of macroH2A represents a rate-limiting step for successful reprogramming in the context of both SCNT and iPSC induction. Given the prominent role of 'active' and 'repressive' histone variants during SCNT, it should be informative to systematically test their function and that of associated chaperones 49 during iPSC generation.
Cell-cell fusion
Downregulation of somatic genes in ES-cell-somatic hybrids also occurs within the first 1-2 days of fusion 93 . When examining the same Oct4-GFP reporter that was used for SCNT and iPSC formation, Oct4 reactivation in fusion hybrids took place with similar kinetics as SCNT (24-48 hours) 93 and this process was reported to involve Tet2 (ref. 94 ).
This finding suggests that ES cells, like oocytes, contain additional reprogramming factors that are limiting during iPSC formation. Corroborating this point, Nanog overexpression promotes cell fusion reprogramming and drives maturation of iPSCs, whereas its absence blunts both types of reprogramming 45 . Surprisingly, Oct4 protein is required, whereas Sox2 protein is dispensable for fusion-mediated reprogramming, identifying a notable difference to induced pluripotency 95 . It is also important to mention that the reprogramming of hybrids is not complete on activation of somatic pluripotency genes 2 days after fusion. Activation of the silenced X chromosome in female hybrids takes several days, which is reminiscent of the delayed X reactivation observed during Xenopus SCNT 96 . Consistently, transcriptome-wide analysis of hybrid formation has documented that some silenced ES-cell-associated genes are activated more rapidly than others 97 . These results are in line with the sequential activation of pluripotency-associated genes during iPSC derivation 4, 5 , and probably reflect different chromatin accessibility of associated genomic loci to ES-cell-derived reprogramming factors.
At the chromatin level, inhibition of the H3K9 HMT G9a or overexpression of the H3K9 HDM Jhdm2a increases cell-fusion-directed reprogramming, which is in accordance with their supportive roles in iPSC generation 98 . Conversely, depletion of PRC1 or PRC2 subunits decreases cell-fusion-mediated reprogramming and induced pluripotency, underscoring the general importance of H3K27me3-mediated gene repression for the acquisition of pluripotency 99 . Collectively, these findings support the interpretation that iPSC formation and cell-fusiondirected reprogramming face similar epigenetic barriers and are stimulated by the same transcription factors, which is consistent with the fact that iPSC factors were initially identified in ES cells 3 . On the basis of accelerated kinetics of pluripotency activation in hybrids compared with nascent iPSCs, it should be feasible to devise genetic screens to identify other Nanog-like molecules that are limiting for efficient transcriptionfactor-induced reprogramming.
Primordial germ cell reprogramming
Primordial germ cell (PGC) maturation represents yet another type of reprogramming that occurs naturally and encompasses major epigenetic remodelling events that prepare the developing germ line for totipotency 100, 101 . Remarkably, PGCs that have completed reprogramming exhibit two active X chromosomes in females 102 , ES-cell-like transcriptional patterns and bivalent domains 103 . This includes expression of potent reprogramming factors, such as Oct4, Sox2, Nanog and Prdm14 (refs 101, 104) . Each of these factors is essential for PGC formation in vivo, although their precise roles in PGC reprogramming remain elusive. Importantly, PGCs are unipotent in vivo (they can only produce oocyte or sperm) but they have the unique potential to give rise to pluripotent stem cells, coined embryonic germ cells (EGCs), on explantation in culture 1 . Expression of these ES-cell-associated transcription factors might thus endow PGCs with the latent ability to acquire pluripotency on isolation from the gonads and exposure to appropriate extracellular cues. Because germ cell reversion into EGCs rarely occurs in vivo, except in cases of spontaneous teratocarcinomas (pluripotent tumours), potent mechanisms must be in place to preserve the PGC state. Blimp1 is a possible candidate molecule, owing to its role as a repressor of c-Myc and Klf4 expression in PGCs 104 . It should be possible to test this hypothesis by assessing whether acute loss of Blimp1 is sufficient to convert PGCs into EGCs in vitro and to cause teratocarcinomas in vivo. Notably, Blimp1's putative role in suppressing the acquisition of a pluripotent state in PGCs might be taken over by the transcription factor Dmrt1 at subsequent stages of male germline development. Male mice lacking this transcription factor in the germ line aberrantly express pluripotency factors and develop testicular teratomas with almost full penetrance 105 . The notion that Blimp1 and Dmrt1 might actively resist acquisition of pluripotency is analogous to the inhibitory effect that somatic transcription factors have during iPSC formation 19 . With respect to chromatin dynamics, global loss of H3K9 methylation is among the most striking changes in developing PGCs 100 . Notably, downregulation of H3K9 HMTs seems to be crucial for efficient reprogramming in the context of PGC specification 101 , cell fusion 98 and iPSC formation 24, 36, 37 . This particular chromatin alteration may therefore represent a general requirement for cellular reprogramming in these very different cellular contexts. Similarly, loss of inhibitory H3K27 methylation at pluripotency loci through catalysis by Utx seems to be another required step during both PGC reprogramming and iPSC formation 14 . Furthermore, pluripotency gene suppression by the NURD component , and Dnmt1 and Dnmt3a depletion 31, 42 on iPSC formation, these data show that the erasure of somatic DNA methylation patterns is a general roadblock for successful epigenetic reprogramming in different cellular settings. Cells use a combination of 'passive' and 'active' DNA demethylation strategies to overcome this barrier, although their relative contribution varies depending on the reprogramming context.
Induced pluripotency and tumorigenesis
Several lines of evidence support the idea that induced pluripotency and transformation are related processes at a cellular level (Box 1). Reprogramming, like cancer, is a rare, multi-step process that ultimately leads to the formation of a small population of immortal cells with tumorigenic potential; iPSCs, like ES cells, have the ability to give rise to teratomas (benign tumours containing derivatives of the three germ layers) on transplantation under the skin of mice 1 . Another similarity between reprogramming and some types of cancer is the observation that somatic stem and progenitor cells are more susceptible to both iPSC formation 109, 110 and tumorigenesis 111, 112 compared with mature cells. This observation may indicate that the epigenetic state of the starting cell provides a permissive environment for both oncogenic and reprogramming factors. Furthermore, transcription-factor-mediated reprogramming induces a metabolic switch from an oxidative to a glycolytic state typical of most cancer cells 113 . Last, teratocarcinomas represent a special type of cancer that originates from transformed PGCs and contains pluripotent cells, documenting a rare example of spontaneous reprogramming of committed (germ) cells into pluripotent malignant cells 1 . An important distinction, however, between these examples of cancer and induced pluripotency is that iPSCs are normal diploid cells that support development when re-introduced into embryos, whereas most cancer cells are aneuploid and characterized by aberrant differentiation patterns. It should thus be informative to study those chromatin and epigenetic events that transiently endow iPSCs with immortality and tumorigenic properties in addition to increased differentiation potential, as this might lead to new strategies to reverse malignancy.
Molecular data support the cellular commonalities between reprogramming and malignancy. First, each of the four classic reprogramming factors has been shown to be oncogenic in mice, and some of these genes are amplified or mutated in human cancer 114 , suggesting that they might destabilize cell state in tumours akin to their role in reprogramming. Chromatin regulators that cooperate with OKSM during reprogramming, such as Jhdm1b and macroH2A, have also been associated with tumorigenesis. Jhdm1b expression has been causally linked with myeloid transformation of haematopoietic progenitors through silencing of the ink4b gene 115 and with pancreatic adenocarcinoma formation through silencing of developmental genes in collaboration with PRC2 (ref. 116) . In contrast to the cancer-and reprogrammingpromoting role of Jhdm1b, expression of macroH2A provides a barrier for both iPSC formation and the malignant progression of melanoma cells. MacroH2A's promoting effect on melanoma invasion is, in part, exerted through upregulation of the cell cycle regulator CDK8, which differs from the pluripotency genes targeted by this histone variant during induced pluripotency 117 . Hence, these and several other examples 114 document that premalignant cells and nascent iPSCs target some of the same chromatin regulators to manipulate cell identity, although their targets may vary.
Both cellular reprogramming and cancer are also characterized by similar global changes in chromatin structure and DNA methylation. Cancer cells, like ES cells, are devoid of LOCKs compared with normal differentiated cells 27 . Given the observation that H3K9 methylation is a major barrier for iPSC formation 24, 36, 37 , this finding suggests that many cancers have acquired a developmentally more primitive epigenetic state that might be required for the maintenance of malignancy. Another hallmark of most cancer genomes is altered methylation patterns, which Here (Box Fig.) reprogramming of somatic cells to pluripotency and transformation of normal cells into malignant cells are illustrated as biochemical reactions with defined reactants (somatic cells and reprogramming factors or cancer genes) and products (iPSCs or cancer cells). Reprogramming is initiated by the overexpression of Oct4, Klf4, Sox2 and c-Myc (OKSM), whereas cellular transformation involves the activation of oncogenes and/or repression of tumour suppressor genes. Intermediates (coloured circles on grey lines) of each reaction remain largely elusive. Both processes need to overcome epigenetic barriers that stabilize the somatic state. Once a certain combination of epigenetic changes have been acquired (analogous to a rise in energy in a biochemical reaction), cells assume a stable new identity (iPSCs or cancer cells). The efficiency of this reaction can be modulated by manipulation of additional genes ('catalyser genes'). At a cellular level, both induced pluripotency and tumorigenesis are multi-step processes that require proliferation and result in a change of cell identity or differentiation potential. The 'end product' is in both cases an immortal cell with tumorigenic potential. However, cancer cells almost always acquire genetic aberrations and become aneuploid whereas iPSCs retain a normal diploid genome. At a molecular level, many cancer cells have, like iPSCs, reduced levels of H3K9 methylation and altered DNA methylation patterns compared with differentiated cells. Overall, these findings suggest that nascent iPSCs and premalignant cells face some of the same epigenetic barriers to alter cell identity. This notion may explain why the same epigenetic regulators, such as Utx, macroH2A, Jhdm1b, Ezh2, Tet2 or Dnmts, are involved in both processes. This idea is also consistent with the finding that certain somatic progenitor and stem cells are more susceptible to tumorigenesis and reprogramming than differentiated cells, indicating a more permissive epigenetic environment (see 'Induced pluripotency and tumorigenesis' for details). can manifest as aberrant hypermethylation or hypomethylation. In this regard, it is interesting to mention that reduced methylation levels, induced by hypomorphic expression of Dnmt1, cause T-cell lymphomas in mice 118 and promote iPSC formation in vitro 42 . Likewise, mutations in DNMT3A have been observed in AML 114 , and knockdown of the gene encoding this enzyme facilitates human reprogramming into iPSCs 31 . These similarities between reprogramming and tumorigenesis are thus further consistent with the view that cancer cells need to override some of the same somatic barriers as iPSCs to alter cellular states.
BOX 1

Induced pluripotency and malignant transformation
Of note, the correlation between reprogramming and cancer is not absolute. In fact, some epigenetic regulators and histone modifications have been shown to have opposite roles during reprogramming and malignancy. For example, loss of Tet2 causes myeloid transformation in mice 119 , consistent with a tumour suppressor function, whereas depletion of Tet2 protein abrogates reprogramming 43 . Similarly, the H3K79 methyltransferase Dot1L promotes leukaemia formation induced by MLL-AF9 translocations 120 , although it prevents iPSC formation 31 . Components of the SWI-SNF complex, which facilitates reprogramming, act as potent tumour suppressors and are frequently mutated in cancer 121 , indicating opposite functions. Last, genome-wide methylation analyses of somatic cells and iPSCs have identified a set of reprogramming-specific differentially methylated regions (R-DMRs), which showed significant overlap with DMRs that changed during the transformation of normal into malignant cells 122 . However, R-DMRs that become hypomethylated and bivalent during iPSC generation are typically hypermethylated in cancer, whereas R-DMRs that become hypermethylated in iPSCs lack bivalent marks and are usually hypomethylated in cancer. Given the importance of bivalently marked genes in multi-lineage differentiation, their methylation silencing in cancer may be a secure way to keep cells in a self-perpetuating undifferentiated state, whereas this change would be detrimental for pluripotency in iPSCs. In summary, the discrepancies between tumorigenesis and reprogramming are probably explained by the strongly stage-and cellcontext dependent roles that these enzymes and their modifications have during tumorigenesis and reprogramming.
A testable prediction based on the above-mentioned observations is that some cancer cells should be susceptible to epigenetic reprogramming into a non-malignant state. Indeed, both SCNT and iPSC experiments demonstrated that malignant cells, such as melanoma 123 and medulloblastoma 124 , can be reprogrammed into a pluripotent state that supports differentiation into a number of normal cell types. Thus, some cancers are not irreversibly locked in a tumorigenic state but instead amenable to epigenetic reversion into a phenotypically normal state.
Outlook
Extensive functional genomics and screening approaches over the past few years have provided important insights into the epigenetic mechanisms that occur during normal, induced and pathological examples of cell fate change. Whereas the drivers of cell fate change may be quite different in distinct contexts (for example, OKSM in reprogramming, unidentified factors during SCNT and oncogenes in tumorigenesis), the resultant chromatin and epigenetic changes leading to altered cell identities are often conserved. This observation probably underlies the fact that different reprogramming approaches face some of the same molecular barriers that have been established during development and terminal differentiation to resist aberrant cell fate changes. We therefore conclude that transcription-factor-induced reprogramming provides a powerful tool to interrogate those chromatin and epigenetic mechanisms that stabilize cell fates during development and that become corrupted in cancer. These analyses have implications for both regenerative medicine and cancer biology. A better understanding of the molecular steps leading to pluripotency and the roadblocks resisting cell fate change in different contexts have already allowed researchers to interfere in a rationalized way with defined molecules or pathways to promote or prevent desired cell fate changes [50] [51] [52] 92 . An interesting challenge in the future will be to isolate and stabilize intermediate stages of reprogramming, which might represent natural or artificial cellular states with increased differentiation potential. Dissecting the molecular roadblocks of reprogramming also has relevance for the study and treatment of cancer. Given that premalignant cells use some of the same epigenetic mechanisms as nascent iPSCs to change cell identity, their manipulation may lead to new strategies that reverse malignancy by altering cellular state rather than cell survival. Although the concept of reprogramming cancer cells to pluripotency has already been demonstrated, additional work is needed to develop more specific approaches that reverse malignant cells into a non-pluripotent state by targeting defined transcription factors or epigenetic regulators. Recent work on the conversion of leukaemia and lymphoma cells into non-tumorigenic, quiescent macrophages by a single transcription factor 125 is a promising step in this direction. ■
